AmerisourceBergen officially has a new name: Cencora.

The healthcare giant announced that it completed its name and stock ticker change Wednesday morning. 

The company said it has started trading under the ticker symbol “COR” on the New York Stock Exchange. During the early morning session of its first day as Cencora, the company’s stock was trading down around 0.4%.

The drug wholesaler said the name “Cencora” underscores its “experience and vision” related to connecting drugmakers, patients, providers and pharmacies with a reliable flow of treatments.

The name change follows more than two decades of the company operating as AmerisourceBergen. Cencora became AmerisourceBergen following the merger of pharma supplier Bergen Brunswig and distributor AmeriSource Health in 2001.

“Today is a significant and exciting milestone for Cencora. Our new name is a reminder of our customers, their patients, and our team members who are at the center of everything we do,” Cencora CEO Steven H. Collis said in a statement. “It represents the healthier futures we strive for serving as a trusted industry partner that prioritizes innovation, advocates for patient access, and advances strategic partnerships across the global pharmaceutical value chain.”

In recognition of the name change, Cencora donated $5 million to the nonprofit Cencora Impact Foundation, formerly known as the AmerisourceBergen Foundation. This donation will launch the Cencora Healthier Futures Grant Program to identify opportunities to support frontline healthcare workers assisting underserved patient populations around the world. 

The first donation from the Cencora Healthier Futures Grant Program will be a $500,000 grant to the UNICEF Health Fund. 

Additionally, the company’s corporate venture fund Cencora Ventures, formerly known as AB Health Ventures, will commit 10% of future realized profits to support the Cencora Impact Foundation.

The company’s pledge to support global health initiatives comes after years of involvement in legal proceedings related to claims its business practices contributed to the deadly, multi-decade opioid epidemic.

In early 2022, AmerisourceBergen and three other large healthcare companies — Johnson & Johnson, Cardinal Health and McKesson — agreed to pay approximately $26 billion to settle a litany of opioid lawsuits. The company is responsible for paying $6.1 billion to 46 participating states over 18 years as part of the settlement.